Endometriosis - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 132
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EE555FFC69CEN
Leaflet:

Download PDF Leaflet

Endometriosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Endometriosis - Pipeline Review, H2 2016’, provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Endometriosis
  • The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects
  • The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Endometriosis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Endometriosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Endometriosis Overview
Therapeutics Development
Pipeline Products for Endometriosis - Overview
Pipeline Products for Endometriosis - Comparative Analysis
Endometriosis - Therapeutics under Development by Companies
Endometriosis - Therapeutics under Investigation by Universities/Institutes
Endometriosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Endometriosis - Products under Development by Companies
Endometriosis - Products under Investigation by Universities/Institutes
Endometriosis - Companies Involved in Therapeutics Development
AbbVie Inc
Addex Therapeutics Ltd
APAvadis Biotechnologies Srl
Astellas Pharma Inc.
Bayer AG
Dongkook Pharmaceutical Co., Ltd.
ElexoPharm GmbH
EndoCeutics, Inc.
Enteris BioPharma, Inc.
Euroscreen S.A.
Evotec AG
Forendo Pharma Limited
GlaxoSmithKline Plc
Kissei Pharmaceutical Co., Ltd.
Lipicard Technologies Limited
Luye Pharma Group Ltd.
Nippon Shinyaku Co., Ltd.
Orphagen Pharmaceuticals, Inc.
Philogen S.p.A.
Repros Therapeutics Inc.
SK Chemicals Co., Ltd.
Takeda Pharmaceutical Company Limited
ValiRx Plc
Endometriosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-1707 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1128688 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bentamapimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit C-Jun for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Endometriosis and Uterine Fibroids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elagolix sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epelsiban besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVE-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-5677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
goserelin biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
goserelin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLH-2109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-6121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIA-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Endometriosis and Hepatic Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGL-2001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relugolix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKI-2670 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telapristone acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetravil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
triptorelin biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vilaprisan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPEA-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endometriosis - Dormant Projects
Endometriosis - Discontinued Products
Endometriosis - Product Development Milestones
Featured News & Press Releases
Aug 05, 2016: Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis
Jul 06, 2016: ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis
Mar 31, 2016: ValiRx is exhibiting and presenting at the prestigious AACR
Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis
Dec 21, 2015: Repros Updates Proellex Program
Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA
Feb 26, 2015: New Endometriosis Patent Grant for ValiRx
Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications
Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201
Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364
Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201
Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 132

LIST OF TABLES

Number of Products under Development for Endometriosis, H2 2016
Number of Products under Development for Endometriosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Endometriosis - Pipeline by AbbVie Inc, H2 2016
Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2016
Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2016
Endometriosis - Pipeline by Astellas Pharma Inc., H2 2016
Endometriosis - Pipeline by Bayer AG, H2 2016
Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016
Endometriosis - Pipeline by ElexoPharm GmbH, H2 2016
Endometriosis - Pipeline by EndoCeutics, Inc., H2 2016
Endometriosis - Pipeline by Enteris BioPharma, Inc., H2 2016
Endometriosis - Pipeline by Euroscreen S.A., H2 2016
Endometriosis - Pipeline by Evotec AG, H2 2016
Endometriosis - Pipeline by Forendo Pharma Limited, H2 2016
Endometriosis - Pipeline by GlaxoSmithKline Plc, H2 2016
Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
Endometriosis - Pipeline by Lipicard Technologies Limited, H2 2016
Endometriosis - Pipeline by Luye Pharma Group Ltd., H2 2016
Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016
Endometriosis - Pipeline by Philogen S.p.A., H2 2016
Endometriosis - Pipeline by Repros Therapeutics Inc., H2 2016
Endometriosis - Pipeline by SK Chemicals Co., Ltd., H2 2016
Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Endometriosis - Pipeline by ValiRx Plc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Endometriosis - Dormant Projects, H2 2016
Endometriosis - Dormant Projects (Contd..1), H2 2016
Endometriosis - Discontinued Products, H2 2016 121

LIST OF FIGURES

Number of Products under Development for Endometriosis, H2 2016
Number of Products under Development for Endometriosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Endometriosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: